Maverick Capital Ltd. Purchases New Position in Charles River Laboratories International, Inc. $CRL

Maverick Capital Ltd. acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the 1st quarter, Holdings Channel reports. The institutional investor acquired 8,178 shares of the medical research company’s stock, valued at approximately $1,411,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Cardinal Capital Management boosted its position in shares of Charles River Laboratories International by 0.6% in the fourth quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock worth $2,180,000 after buying an additional 62 shares during the period. Asset Management One Co. Ltd. grew its stake in shares of Charles River Laboratories International by 4.0% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock valued at $375,000 after buying an additional 71 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in shares of Charles River Laboratories International by 1.3% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock valued at $1,260,000 after buying an additional 80 shares during the period. Advisory Services Network LLC raised its holdings in shares of Charles River Laboratories International by 2.6% during the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock valued at $505,000 after buying an additional 83 shares during the period. Finally, Brown Miller Wealth Management LLC lifted its position in Charles River Laboratories International by 7.0% during the 1st quarter. Brown Miller Wealth Management LLC now owns 1,278 shares of the medical research company’s stock worth $220,000 after acquiring an additional 84 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Evercore restated an “outperform” rating and issued a $220.00 price target on shares of Charles River Laboratories International in a report on Friday, May 8th. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Royal Bank Of Canada started coverage on shares of Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price on the stock. Mizuho upped their target price on shares of Charles River Laboratories International from $192.00 to $230.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Finally, Barclays raised their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Eleven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $220.75.

Charles River Laboratories International Trading Down 0.9%

Shares of CRL opened at $224.50 on Tuesday. The company has a market capitalization of $10.81 billion, a P/E ratio of -59.71, a P/E/G ratio of 2.52 and a beta of 1.40. Charles River Laboratories International, Inc. has a one year low of $144.26 and a one year high of $238.85. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The stock has a 50-day moving average price of $200.29 and a 200 day moving average price of $187.42.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. During the same period in the previous year, the business earned $2.34 EPS. Charles River Laboratories International’s revenue for the quarter was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the sale, the director owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.